Biotech Values

[midastouch017]

BiondVax ( BVXV)-has spent years developing and testing its potential universal flu vaccine M-001, and now it’s nearly ready to report efficacy results. After starting a massive phase 3 study in eastern Europe back in 2018, the drugmaker expects to report efficacy between late September and the end of October.

For the study, the company tested its vaccine candidate in more than 12,000 adults age 50 and older in seven countries over the span of two flu seasons.

If the results come in positive, BiondVax plans to seek marketing approval in Europe and the U.S., CEO Ron Babecoff said an in interview. The vaccine doesn’t induce the immune system to create antibodies, but instead induces cellular immunity, the CEO explained. It’s made up of nine common peptides that are a “common denominator” of flu strains, Babecoff said.

https://www.fiercepharma.com/special-report/biondvax-m-001